Company intelligence / Profile preview

Rea Diagnostics

Lausanne, Vaud, Switzerland

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Rea Diagnostics has developed a wearable diagnostic device—a smart sanitary pad—that detects biomarkers in vaginal discharge to identify the risk of preterm birth. The technology enables early intervention by healthcare providers and aims to reduce neonatal mortality and morbidity. Clinical validation led by experts at Lausanne University Hospital is ongoing

Therapeutic areas: Women's Health
Modalities: DeviceWearable diagnostic technology
Industry: Physiological Monitoring

Partnerships

Collaborations with Lausanne University Hospital (CHUV)Swiss Federal Institute of Technology Lausanne (EPFL)

Beyond the preview

Go deeper on Rea Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rea Diagnostics.

Explore the full profile